Siri | Glimstad

NEW YORK | MIAMI | LOS ANGELES | PHOENIX

DETROIT | AUSTIN | WASHINGTON D.C.

745 Fifth Ave, Suite 500, New York, NY 10151 sirillp.com | P: (212) 532-1091 | F: (646) 417-5967

FDA FREEDOM OF INFORMATION ACT REQUEST

VIA ONLINE PORTAL

April 9, 2024

Food and Drug Administration Division of Freedom of Information Office of the Secretariat, OC 5630 Fishers Lane, Room 1035 Rockville, MD 20857

Re: Panzyga Clinical Trial Records (IR#1134)

Dear Sir or Madam:

This firm represents Informed Consent Action Network ("ICAN"). On behalf of ICAN, please provide the following records to foia@sirillp.com in electronic form:

All clinical trial documents relied upon by FDA to approve the use of Pfizer/ Octapharma's Immune Globulin Intravenous (Human)-ifas 10% (Panzyga) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP), including but not limited to:

- (1) BLA Efficacy Supplement
- (2) Final Clinical Study Report (CSR) for Study NGAM-08 (NCT02638207)
- (3) Clinical Trial Protocol for Study NGAM-08

Information helpful to fulfilling the request: On February 11, 2021, FDA approved Panzyga for the treatment of adults with CIDP. ICAN is seeking all clinical trial documents relied upon by FDA to grant the approval.

We ask that you waive any and all fees or charges pursuant to 5 U.S.C. § 552(a)(4)(A)(iii). ICAN is a not-for-profit news media organization whose mission is to raise public awareness about vaccine safety, other medical treatments, environmental pollutants and toxins, and overall health choices, and to provide the public with information needed in order to give informed consent. As

¹ See https://www.fda.gov/media/145883/download.

part of its mission, ICAN actively investigates and disseminates scientifically-based health information regarding the safety of vaccines, other medical treatments, environmental pollutants and toxins, and governmental activities for free through its website,² a weekly health news and talk show,³ and through press events and releases. The HighWire website has approximately 3.4 million weekly visitors. On X (formerly known as Twitter), The High Wire has approximately 190,000 followers and 1 to 2.5 million impressions in a 28-day period. On Rumble, The HighWire has approximately 83,000 followers and growing. The size of ICAN's audience and subscribers continues to grow and is illustrative of the wide public interest in the subject of health and medical safety. Critical to ICAN's mission is its proven ability to find and review critical scientific and governmental records and meaningfully report about their social impacts. One of the tools ICAN uses to gather the raw material it uses in its popular investigative reporting is the Freedom of Information Act (FOIA). ICAN is seeking the information in this FOIA request to allow it to contribute to the public understanding of government programs and any potential effects of same on public health. The information ICAN is requesting will not contribute to any commercial activities. Therefore, ICAN should be properly categorized as a media requester, and it is entitled to the search and processing privileges associated with such a category designation. Accordingly, ICAN will be forced to challenge any agency decision that categorizes it as any other category of requester.

Please note that the FOIA provides that if only portions of a requested file are exempted from release, the remainder must still be released. We therefore request that we be provided with all non-exempt portions which are reasonably segregable. We further request that you describe any deleted or withheld material in detail and specify the statutory basis for the denial as well as your reasons for believing that the alleged statutory justification applies. Please also separately state your reasons for not invoking your discretionary powers to release the requested documents in the public interest. Such statements may help to avoid unnecessary appeal and litigation. ICAN reserves all rights to appeal the withholding or deletion of any information.

Access to the requested records should be granted within twenty (20) business days from the date of your receipt of this letter. Failure to respond in a timely manner shall be viewed as a denial of this request and ICAN may immediately take further administrative or legal action.

Furthermore, we specifically request that the agency provide us with an estimated date of completion for this request.

If you would like to discuss our request or any issues raised in this letter, please feel free to contact us at (212) 532-1091 or foia@sirillp.com during normal business hours. Thank you for your time and attention to this matter.

² https://www.icandecide.org/.

³ https://thehighwire.com/.